Persistence of antibody at 18 months following vaccination of young Gambian infants with PRP-OMPCHaemophilus influenzaetype b conjugate vaccine

Publisher Website
Google Scholar
Abstract
The rate of decline in anti-PRP antibody levels was measured in two groups of Gambian children who had been given PRP-OMPC at 1 and 3 months or 2 and 4 months of age. In the younger group (n = 70), the geometric mean titre fell from 1.32 μg/ml at 4 months to 0.44 μg/ml at 18 months. In the older group (n = 54), the geometric mean titre fell from 1.18 μg/ml at 5 months to 0.46 μg/ml at 18 months. The proportion of vaccinated children with antibody levels over 1.0 μg/ml fell from 54% 1 month after the second dose of vaccine to 27% at the age of 18 months' while the proportion with levels over 0.15 μg/ml fell from 82% to 60%, with no significant differences observed between the vaccination groups. For those children who did not show evidence of environmental boosting, the half-life of anti-PRP antibody was about 100 days. This did not differ between the groups. These findings suggest that to provide lasting immunity PRP-OMPC should be given with a late booster dose at 12–15 months, as is the current practice in the USA. The need for a late booster dose may limit the value of this vaccine in developing countries where vaccination of children is difficult after the 1st year of life.

This publication has 11 references indexed in Scilit: